About this trial
The most frequent crystal arthropathy is gout, which is also the most prevalent cause of inflammatory arthritis. Gouty Patients frequently have excruciating pain and swelling in their joints. Gout is linked to decreased health-related quality of life and functional disability. Gout and its associated diseases have been shown to have a significant impact on patients mortality and morbidities. Metformin, a biguanide, is used to manage diabetes by reducing insulin resistance and preventing comorbidities such as cerebrovascular and coronary artery disease, as well as providing renal protection to diabetic nephropathy patients
Eligibility criteria
Qualifiers
Gouty patients clinically diagnosed as gouty arthritis based on the American College of Rheumatology/European League Against Rheumatism criteria of gout.
Disqualifiers
Systemic disorders such as cardiovascular, neurological, coronary artery disease.
Hypertension, hyperlipidemia, diabetes mellitus, active infections.
Other inflammatory or autoimmune diseases.
Patients on biologics,
Trial design
Treatments tested in this trial
- placebo
- Metformin
Treatment groups
Sponsors and collaborators
Mostafa Bahaa
Lead sponsor
Tanta University
Sponsor institution